Product news

Share this article:

Pfizer granted a royalty-free license to the International Partnership for Microbicides (IPM) to try to develop Selzentry (maraviroc) in a cream or gel for the prevention of HIV infection. The agreement enables IPM to develop, manufacture and distribute a maraviroc-based microbicide in developing countries. Microbicides are products that could be applied vaginally or anally to prevent transmission of the human immunodeficiency virus that causes AIDS. Pfizer's CCR5 blocker was approved last August. The microbicides group also has agreements with Ortho Biotech unit Tibotec Pharmaceuticals, Merck, Bristol-Myers Squibb and Gilead Sciences to develop some of their HIV drugs. Pfizer granted a royalty-free license to the International Partnership for Microbicides (IPM) to try to develop Selzentry (maraviroc) in a cream or gel for the prevention of HIV infection. The agreement enables IPM to develop, manufacture and distribute a maraviroc-based microbicide in developing countries. Microbicides are products that could be applied vaginally or anally to prevent transmission of the human immunodeficiency virus that causes AIDS. Pfizer's CCR5 blocker, approved last August, was the second FDA-sanctioned drug licensed by IPM. The first was the Bristol-Myers Squibb/Gilead Sciences antiviral Viread (tenofovir). The microbicides group also has agreements with Ortho Biotech unit Tibotec Pharmaceuticals and with Merck to develop some of their HIV drugs.

 Intelence (etravirine), from J&J subsidiary Tibotec Pharmaceuticals, was approved for treating HIV infection in adults who have failed treatment with other antiretrovirals. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that helps to block an enzyme which HIV needs to multiply. The drug, approved for use in combination with other anti-HIV medications, received a priority review by the FDA.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.